Browsed by
Tag: Therapeutics

Thinking about buying stock in DouYu, Adamis Pharmaceuticals, Altimmune, FuelCell Energy, or Ovid Therapeutics?

Thinking about buying stock in DouYu, Adamis Pharmaceuticals, Altimmune, FuelCell Energy, or Ovid Therapeutics?

Thinking about buying stock in DouYu, Adamis Pharmaceuticals, Altimmune, FuelCell Energy, or Ovid Therapeutics?

Thinking about buying stock in DouYu, Adamis Pharmaceuticals, Altimmune, FuelCell Energy, or Ovid Therapeutics?

PR Newswire

NEW YORK, Oct. 12, 2020

NEW YORK, Oct. 12, 2020 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for DOYU, ADMP, ALT, FCEL, and OVID.



To see how InvestorsObserver’s proprietary scoring system rates these stocks, view the InvestorsObserver’s PriceWatch Alert by selecting the corresponding link.

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver’s PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock’s overall suitability for investment.


View original content to download multimedia:http://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-douyu-adamis-pharmaceuticals-altimmune-fuelcell-energy-or-ovid-therapeutics-301150213.html

SOURCE InvestorsObserver

Source Article Read the rest

Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics

Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics

On September 14, 2020, Avalanche Merger Sub, Inc., a wholly-owned subsidiary of Ionis, commenced a tender offer to acquire all of the outstanding shares of Akcea at a price of $18.15 per share in cash, without interest and subject to withholding of taxes. The tender offer expired at one minute after 11:59 p.m., Eastern Time, on October 9, 2020 and was not extended. Ionis accepted for payment all shares tendered and not validly withdrawn in the offer and will promptly pay for such shares, which represented approximately 85.5% of the outstanding shares of Akcea’s common stock not already owned by Ionis.

After the completion of the tender offer, Avalanche Merger Sub merged with and into Akcea on October 12, 2020, with Akcea surviving as a wholly owned subsidiary of Ionis.  All shares of Akcea not held by Ionis, Akcea, any wholly owned subsidiary of Ionis, or stockholders of Akcea who have perfected their statutory appraisal rights under Delaware law, were converted into the right to receive $18.15 per share in cash, as was paid in the tender offer.

ADVISORS

Goldman Sachs & Co. LLC and Stifel, Nicolaus, & Company, Incorporated served as financial advisors to Ionis, and Skadden, Arps, Slate, Meagher & Flom LLP served as legal counsel to Ionis. Cowen served as financial advisor to the Affiliate Transactions Committee of Akcea’s Board of Directors, and Ropes & Gray LLP served as legal counsel to the Affiliate Transactions Committee of Akcea’s Board of Directors.

ABOUT IONIS PHARMACEUTICALS, INC.

As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope

Read the rest
Sorrento Therapeutics (SRNE) Outpaces Stock Market Gains: What You Should Know

Sorrento Therapeutics (SRNE) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Sorrento Therapeutics (SRNE) closed at $11.29, marking a +0.98% move from the previous day. This move outpaced the S&P 500’s daily gain of 0.88%. Meanwhile, the Dow gained 0.57%, and the Nasdaq, a tech-heavy index, added 1.39%.

Heading into today, shares of the biopharmaceutical company had gained 81.12% over the past month, outpacing the Medical sector’s gain of 3.5% and the S&P 500’s gain of 3.54% in that time.

SRNE will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of -$0.21, up 50% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $10.32 million, up 78.46% from the year-ago period.

For the full year, our Zacks Consensus Estimates are projecting earnings of $4.96 per share and revenue of $2.05 billion, which would represent changes of +333.96% and +6411.95%, respectively, from the prior year.

Investors should also note any recent changes to analyst estimates for SRNE. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company’s business and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. SRNE is holding a Zacks Rank of #4 (Sell) right now.

Investors should also note SRNE’s current valuation metrics, including its Forward P/E ratio

Read the rest
Applied Therapeutics Inc. (APLT) Stock Sinks As Market Gains: What You Should Know

Applied Therapeutics Inc. (APLT) Stock Sinks As Market Gains: What You Should Know

Applied Therapeutics Inc. (APLT) closed at $22.86 in the latest trading session, marking a -0.95% move from the prior day. This move lagged the S&P 500’s daily gain of 0.88%. Elsewhere, the Dow gained 0.57%, while the tech-heavy Nasdaq added 1.39%.

Prior to today’s trading, shares of the company had lost 5.87% over the past month. This has lagged the Medical sector’s gain of 3.5% and the S&P 500’s gain of 3.54% in that time.

Wall Street will be looking for positivity from APLT as it approaches its next earnings report date. In that report, analysts expect APLT to post earnings of -$0.84 per share. This would mark a year-over-year decline of 33.33%.

Investors should also note any recent changes to analyst estimates for APLT. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company’s business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. APLT is currently a Zacks Rank #4 (Sell).

The Medical – Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 185, which puts it in the bottom 27% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks

Read the rest